141 related articles for article (PubMed ID: 20371457)
21. The G972R variant of the insulin receptor substrate-1 gene impairs insulin signaling and cell differentiation in 3T3L1 adipocytes; treatment with a PPARgamma agonist restores normal cell signaling and differentiation.
Sentinelli F; Filippi E; Cavallo MG; Romeo S; Fanelli M; Baroni MG
J Endocrinol; 2006 Feb; 188(2):271-85. PubMed ID: 16461553
[TBL] [Abstract][Full Text] [Related]
22. Reduced cardiotropic response to insulin in spontaneously hypertensive rats: role of peroxisome proliferator-activated receptor-gamma-initiated signaling.
Zhang H; Li J; Li R; Zhang Q; Ma H; Ji Q; Guo W; Wang H; Lopez BL; Christopher TA; Ma X; Gao F
J Hypertens; 2008 Mar; 26(3):560-9. PubMed ID: 18300869
[TBL] [Abstract][Full Text] [Related]
23. Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2.
Wakino S; Hayashi K; Kanda T; Tatematsu S; Homma K; Yoshioka K; Takamatsu I; Saruta T
Circ Res; 2004 Sep; 95(5):e45-55. PubMed ID: 15308580
[TBL] [Abstract][Full Text] [Related]
24. The effect of PPARgamma ligands on the adipose tissue in insulin resistance.
Hammarstedt A; Andersson CX; Rotter Sopasakis V; Smith U
Prostaglandins Leukot Essent Fatty Acids; 2005 Jul; 73(1):65-75. PubMed ID: 15936183
[TBL] [Abstract][Full Text] [Related]
25. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
26. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE
Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480
[TBL] [Abstract][Full Text] [Related]
27. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
28. The pharmacological treatment of pulmonary arterial hypertension.
Frumkin LR
Pharmacol Rev; 2012 Jul; 64(3):583-620. PubMed ID: 22659328
[TBL] [Abstract][Full Text] [Related]
29. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone attenuates oxyhemoglobin-induced Toll-like receptor 4 expression in vascular smooth muscle cells.
Wu Y; Zhao XD; Zhuang Z; Xue YJ; Cheng HL; Yin HX; Shi JX
Brain Res; 2010 Mar; 1322():102-8. PubMed ID: 20132800
[TBL] [Abstract][Full Text] [Related]
30. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
31. PPARgamma in endothelial cells influences high fat diet-induced hypertension.
Nicol CJ; Adachi M; Akiyama TE; Gonzalez FJ
Am J Hypertens; 2005 Apr; 18(4 Pt 1):549-56. PubMed ID: 15831367
[TBL] [Abstract][Full Text] [Related]
32. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering.
Mawatari E; Hongo M; Sakai A; Terasawa F; Takahashi M; Yazaki Y; Kinoshita O; Ikeda U
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):594-600. PubMed ID: 17581214
[TBL] [Abstract][Full Text] [Related]
33. PPARγ is a gatekeeper for extracellular matrix and vascular cell homeostasis: beneficial role in pulmonary hypertension and renal/cardiac/pulmonary fibrosis.
Kökény G; Calvier L; Legchenko E; Chouvarine P; Mózes MM; Hansmann G
Curr Opin Nephrol Hypertens; 2020 Mar; 29(2):171-179. PubMed ID: 31815758
[TBL] [Abstract][Full Text] [Related]
34. PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation.
Legchenko E; Chouvarine P; Borchert P; Fernandez-Gonzalez A; Snay E; Meier M; Maegel L; Mitsialis SA; Rog-Zielinska EA; Kourembanas S; Jonigk D; Hansmann G
Sci Transl Med; 2018 Apr; 10(438):. PubMed ID: 29695452
[TBL] [Abstract][Full Text] [Related]
35. Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension.
Chaumais MC; Guignabert C; Savale L; Jaïs X; Boucly A; Montani D; Simonneau G; Humbert M; Sitbon O
Am J Cardiovasc Drugs; 2015 Feb; 15(1):13-26. PubMed ID: 25421754
[TBL] [Abstract][Full Text] [Related]
36. Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.
Oishi P; Datar SA; Fineman JR
Expert Opin Pharmacother; 2011 Aug; 12(12):1845-64. PubMed ID: 21609302
[TBL] [Abstract][Full Text] [Related]
37. Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.
Tseng V; Sutliff RL; Hart CM
Antioxid Redox Signal; 2019 Oct; 31(12):874-897. PubMed ID: 30582337
[No Abstract] [Full Text] [Related]
38. Treatment of pulmonary arterial hypertension with targeted therapies.
O'Callaghan DS; Savale L; Montani D; Jaïs X; Sitbon O; Simonneau G; Humbert M
Nat Rev Cardiol; 2011 Jul; 8(9):526-38. PubMed ID: 21769113
[TBL] [Abstract][Full Text] [Related]
39. PPARgamma as a potential therapeutic target in pulmonary hypertension.
Sutliff RL; Kang BY; Hart CM
Ther Adv Respir Dis; 2010 Jun; 4(3):143-60. PubMed ID: 20530063
[TBL] [Abstract][Full Text] [Related]
40. Anti-inflammatory and immunosuppressive agents in PAH.
Meloche J; Renard S; Provencher S; Bonnet S
Handb Exp Pharmacol; 2013; 218():437-76. PubMed ID: 24092351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
